Home › Services › Differentiation Benchmarks
EVIDENCE STRATEGY

Differentiation Benchmarks

What your asset has to show to win, set against the published evidence and the payer record.

WHEN
Before a Phase 3 design is fixed, an in-licensing decision, a partnering round or investor diligence.
THERAPY AREAS
Oncology, rare disease and specialty medicines: any population where comparators have published randomised or single-arm data.
OVERVIEW

A differentiation benchmark fixes the patient population first, picks the handful of outcomes that decide the market, and sets your asset's minimum, target and aspirational profile against the published evidence for the standard of care and the strongest competitor. It answers the question every Phase 3 design, licensing deal and investor memo turns on: what does this asset have to show to win?

WHEN TO USE IT

Is this the right model for you?

WHAT WE DELIVER

What's included

Population and comparators
the decision-relevant population and comparator set, taken from registry eligibility criteria and approved labels
Benchmark grid
efficacy, safety and treatment burden on one scale per outcome, with better always in the same direction
Comparability flags
evidence maturity, control-arm drift and definition differences marked, so a cross-trial comparison is never mistaken for a head-to-head
Concept range
minimum, target and aspirational values for each outcome, with the reasoning written down
Forward view
every running Phase 3 in the population with its registered completion date, so the bar is set for launch rather than for today
HTA precedents
how NICE, SMC, PBAC, HAS and G-BA treated each comparator, and where the EU joint clinical assessment will apply to your asset
Price headroom
the price each point on the concept range supports against payer thresholds, from a cost-effectiveness model
Source pack
every plotted value with its trial, evidence level and citation, in a table your team can audit
WORKED EXAMPLE

Ulcerative colitis

We built one on public data for a hypothetical new advanced therapy in moderately to severely active ulcerative colitis. It shows three things a target product profile set against placebo alone would miss.

  • NICE has recommended all ten medicines it has appraised individually in this population since 2015, the last five with an instruction to use the least expensive suitable option, while the G-BA found added benefit not proven for all nine it assessed.
  • Placebo arms move the answer: four medicines reach about 50% remission at one year, yet read as anything from a 25-point to a 41-point gain.
  • With twelve Phase 3s running or about to start, two of them head to head, the comparator at launch is unlikely to be the comparator today.
SEE THE WORKED EXAMPLE ›
HOW IT IS BUILT

Open sources, every figure cited

Benchmarks are built from ClinicalTrials.gov, regulatory approvals and labels, peer-reviewed publications, congress abstracts and company releases where no full paper exists, and the HTA agencies' own decision records, including our database of 23,515 decisions. Because the sources are open, every figure can sit in a board paper, an investor deck or a submission with its citation beside it.

PRICING

Fee tiers

TIER
FEE
TIMELINE
Benchmark
Population, comparator set and benchmark grid, with concept range and source pack
 
£8,000-12,000
2-3 weeks
Benchmark and forward view
Adds the running Phase 3 pipeline and HTA precedents for each comparator
 
£14,000-20,000
3-4 weeks
Benchmark and value
Adds price headroom at the minimum, target and aspirational profiles, up to three markets
 
£28,000-45,000
6-8 weeks

All fees are fixed price. Scope, deliverables and timeline are agreed before work begins. Further populations or markets are quoted on request.

Ready to discuss your asset?

Tell us the indication, the line of therapy and the decision the benchmark has to support.
We'll come back to you within one working day.

BOOK A SCOPING CALL